BACKGROUND: Pulmonary hypertension (PHT) is reported to be associated with measures of renal function in patients with sickle cell disease (SCD). The purpose of this exploratory study was to determine the relationship between albuminuria and both clinical and laboratory variables in SCD. DESIGN AND METHODS: This cross-sectional study was performed using a cohort of adult patients with SCD and control subjects without SCD. Spot urine for microalbumin/creatinine ratio, measures of hemolysis, inflammation and other laboratory studies were obtained. Pulmonary artery systolic pressure was determined by Doppler echocardiography, and the diagnosis of PHT was defined using age-, sex- and body mass index-adjusted reference ranges. RESULTS: Seventy-three patients with SCD and 21 healthy, race-matched control subjects were evaluated. In patients with SCD, normoalbuminuria was observed in 34 patients (46.6%), microalbuminuria in 24 patients (32.9%) and macroalbuminuria in 15 patients (20.5%). There was a significant correlation between urine albumin excretion and age. In patients with HbSS and Sbeta(0) thalassemia, the levels of sFLT-1, soluble VCAM and NT pro-BNP were significantly higher in those with macroalbuminuria, compared to patients with microalbuminuria and normoalbuminura, but no significant differences were observed in the levels of laboratory measures of hemolysis. Urine albumin excretion was associated with PHT and a history of stroke. CONCLUSIONS: Our study confirms the high prevalence of albuminuria in SCD. The association of urine albumin excretion with sFLT-1 suggests that this vascular endothelial growth factor receptor family member may contribute to the development of albuminuria in SCD. By inducing endothelial activation and endothelial dysfunction, sFLT-1 appears to be a link between glomerulopathy and PHT in SCD.
BACKGROUND:Pulmonary hypertension (PHT) is reported to be associated with measures of renal function in patients with sickle cell disease (SCD). The purpose of this exploratory study was to determine the relationship between albuminuria and both clinical and laboratory variables in SCD. DESIGN AND METHODS: This cross-sectional study was performed using a cohort of adult patients with SCD and control subjects without SCD. Spot urine for microalbumin/creatinine ratio, measures of hemolysis, inflammation and other laboratory studies were obtained. Pulmonary artery systolic pressure was determined by Doppler echocardiography, and the diagnosis of PHT was defined using age-, sex- and body mass index-adjusted reference ranges. RESULTS: Seventy-three patients with SCD and 21 healthy, race-matched control subjects were evaluated. In patients with SCD, normoalbuminuria was observed in 34 patients (46.6%), microalbuminuria in 24 patients (32.9%) and macroalbuminuria in 15patients (20.5%). There was a significant correlation between urine albumin excretion and age. In patients with HbSS and Sbeta(0) thalassemia, the levels of sFLT-1, soluble VCAM and NT pro-BNP were significantly higher in those with macroalbuminuria, compared to patients with microalbuminuria and normoalbuminura, but no significant differences were observed in the levels of laboratory measures of hemolysis. Urine albumin excretion was associated with PHT and a history of stroke. CONCLUSIONS: Our study confirms the high prevalence of albuminuria in SCD. The association of urine albumin excretion with sFLT-1 suggests that this vascular endothelial growth factor receptor family member may contribute to the development of albuminuria in SCD. By inducing endothelial activation and endothelial dysfunction, sFLT-1 appears to be a link between glomerulopathy and PHT in SCD.
Authors: Nan Hee Kim; Jeong Heon Oh; Ji A Seo; Kye Won Lee; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Young Sun Kang; Sang Youb Han; Kum Hyun Han; Yi Hwa Ji; Dae Ryong Cha Journal: Kidney Int Date: 2005-01 Impact factor: 10.612
Authors: Saif Anwaruddin; Donald M Lloyd-Jones; Aaron Baggish; Annabel Chen; Daniel Krauser; Roderick Tung; Claudia Chae; James L Januzzi Journal: J Am Coll Cardiol Date: 2005-12-09 Impact factor: 24.094
Authors: Ofelia Alvarez; Brenda Montane; Gabriela Lopez; James Wilkinson; Tracie Miller Journal: Pediatr Blood Cancer Date: 2006-07 Impact factor: 3.167
Authors: Roberto F Machado; Anastasia Anthi; Martin H Steinberg; Duane Bonds; Vandana Sachdev; Gregory J Kato; Angelo M Taveira-DaSilva; Samir K Ballas; William Blackwelder; Xiuli Xu; Lori Hunter; Bruce Barton; Myron Waclawiw; Oswaldo Castro; Mark T Gladwin Journal: JAMA Date: 2006-07-19 Impact factor: 56.272
Authors: O S Platt; D J Brambilla; W F Rosse; P F Milner; O Castro; M H Steinberg; P P Klug Journal: N Engl J Med Date: 1994-06-09 Impact factor: 91.245
Authors: Carmen De Miguel; Joshua S Speed; Malgorzata Kasztan; Eman Y Gohar; David M Pollock Journal: Curr Opin Nephrol Hypertens Date: 2016-01 Impact factor: 2.894
Authors: Payal C Desai; Ryan C May; Susan K Jones; Dell Strayhorn; Melissa Caughey; Alan Hinderliter; Kenneth I Ataga Journal: Br J Haematol Date: 2013-07-06 Impact factor: 6.998
Authors: Santosh L Saraf; Xu Zhang; Tamir Kanias; James P Lash; Robert E Molokie; Bharvi Oza; Catherine Lai; Julie H Rowe; Michel Gowhari; Johara Hassan; Joseph Desimone; Roberto F Machado; Mark T Gladwin; Jane A Little; Victor R Gordeuk Journal: Br J Haematol Date: 2013-12-12 Impact factor: 6.998
Authors: Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik Journal: Blood Adv Date: 2020-04-14